Thrombopoietin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Thrombopoietin
Accession Number
DB06534
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description
Not Available
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
5651J3R2JF
CAS number
9014-42-0

Pharmacology

Indication

Investigated for use/treatment in thrombocytopenia.

Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UThrombopoietin receptorNot AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
CyclophosphamideThe risk or severity of pulmonary toxicity can be increased when Thrombopoietin is combined with Cyclophosphamide.
VinblastineThe risk or severity of peripheral neuropathy can be increased when Thrombopoietin is combined with Vinblastine.
VincamineThe risk or severity of peripheral neuropathy can be increased when Thrombopoietin is combined with Vincamine.
VincristineThe risk or severity of peripheral neuropathy can be increased when Thrombopoietin is combined with Vincristine.
VindesineThe risk or severity of peripheral neuropathy can be increased when Thrombopoietin is combined with Vindesine.
VinflunineThe risk or severity of peripheral neuropathy can be increased when Thrombopoietin is combined with Vinflunine.
VinorelbineThe risk or severity of peripheral neuropathy can be increased when Thrombopoietin is combined with Vinorelbine.
VintafolideThe risk or severity of peripheral neuropathy can be increased when Thrombopoietin is combined with Vintafolide.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Thrombopoietin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentLiver Cirrhosis1
1CompletedSupportive CareMalignancies1
1, 2CompletedTreatmentCancer, Breast / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic/Myeloproliferative Diseases1
1, 2CompletedTreatmentGerm Cell Tumors / Hepatic neoplasms malignant / Neuroblastomas / Rhabdomyosarcomas / Sarcoma, Osteogenic1
1, 2RecruitingPreventionHematopoietic Stem Cell Transplantation (HSCT) / Mobilization of hematopoietic stem cells therapy / Thrombocytopoietin1
2Not Yet RecruitingTreatmentAplastic Anaemia (AA)1
2, 3TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3Unknown StatusTreatmentHematological Diseases / Thrombocytopenias1
3CompletedTreatmentIdiopathic Thrombocytopenic Purpura (ITP) / Purpura3
3CompletedTreatmentImmune Thrombocytopenia1
3Not Yet RecruitingTreatmentHematologic Diseases / Thrombocytopenias1
3Not Yet RecruitingTreatmentImmune Thrombocytopenia1
3Unknown StatusTreatmentIdiopathic Thrombocytopenic Purpura (ITP) / Immune Thrombocytopenia / Thrombocytopenias1
3WithdrawnTreatmentIdiopathic Thrombocytopenic Purpura (ITP) / Purpura1
4CompletedTreatmentThrombocytopenia After Chemotherayp in AML / Thrombocytopenias1
4RecruitingTreatmentAllogeneic peripheral haematopoietic stem cell transplant / Delayed Platelet Engraftment / Myeloablative1
4RecruitingTreatmentAplastic Anaemia (AA)1
4RecruitingTreatmentThrombocytopenias1
Not AvailableCompletedTreatmentNeoplasms, Gynecologic1
Not AvailableRecruitingNot AvailableHemostatic Disorders1
Not AvailableRecruitingNot AvailableImmune Thrombocytopenia1
Not AvailableRecruitingTreatmentMultiple Myeloma (MM)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Transmembrane signaling receptor activity
Specific Function
Receptor for thrombopoietin. May represent a regulatory molecule specific for TPO-R-dependent immune responses.
Gene Name
MPL
Uniprot ID
P40238
Uniprot Name
Thrombopoietin receptor
Molecular Weight
71244.08 Da

Drug created on March 19, 2008 10:36 / Updated on September 02, 2019 18:21